ANN ARBOR, Mich., Sept. 21 /PRNewswire/ -- Genomic Solutions Inc. (Nasdaq: GNSL - news), a leading, worldwide supplier of automated solutions for genomic and proteomic research, announces the opening of its new, state-of- the-art Proteomic Center located at the Ann Arbor headquarters.* (Photo: newscom.com )
The Proteomic Center's research and development, contract research services and reagent manufacturing labs are currently operative and supplying products and services to customers around the world. GSI has hired skilled personnel with the experience required to offer high quality in-house proteomic research services from customer project planning to full protein characterization. The lab has the capacity to run hundreds of large format 2-D gels per week and identify and characterize thousands of proteins. Tools used include several methods of prefractionation followed by either 1-D or large format 2D gel electrophoresis with both IEF and IPG first dimension. Following separation, the entire automated Investigator Proteomic System for gel staining, imaging, analysis, plug excision, digestion and spotting to MALDI targets is used to provide maximum throughput and reproducibility. A full complement of Mass Spectrometers is used including ion trap MS, MALDI-TOF MS and LC-MS/MS for protein characterization, identification and de-novo sequencing {in gel sequencing}.
``The business is growing rapidly, and now our new Proteomic Center provides us with the state of the art infrastructure and highly skilled personnel we will require to sustain our growth,'' says Christine Ethier, Vice President of the Proteomics Business Unit at Genomic Solutions. ``Our goal is to be the premier proteomic automation company and fee-for-service protein characterization laboratory in the marketplace. We have made a major investment in the infrastructure required to accomplish this including a more than doubling of our staff of highly recruited scientists.'' To that end, Genomic Solutions has announced the following appointments within its Proteomics Business Unit:
Michael Pisano, Ph.D., recently joined Genomic Solutions as Vice President of Proteomic Research and Development. Dr. Pisano comes to GSI from Aventis Pharmaceuticals where he was head of the Protein Sciences Group. The Group was responsible for proteomic projects within the company as well as development and implementation of proteomic technologies.
Beth Allen, Ph.D., has joined Genomic Solutions as Director of Proteomic Research Services. She is responsible for operation of the Proteomic Research Service Laboratory. Dr. Allen played a key role in the initiation and implementation of a proteomic facility at Los Alamos National Laboratories.
Rick Edmondson, Ph.D., has joined Genomic Solutions as Director of the Protein Mass Spectrometry Group. Dr. Edmondson was previously responsible for the mass spectrometry portion of the Protein Sciences group at Aventis Pharmaceuticals. He is now responsible for the operations of the Protein Mass Spectrometry Group in Proteomic R&D.
In addition, the Proteomic Center is staffed with several other Ph.D. and bachelor level staff scientists and technicians recruited from academia and industry.
``We now have the most sophisticated proteomic instruments available, plus the experienced people to operate them,'' Dr. Pisano notes.
``The Proteomic Center offers a unique situation in which we provide research services on a contractual basis and, if so desired, the technology and products can actually be transferred to the customer. This also allows the development of proteomic technologies to be driven by the needs of researchers with whom we will be involved on a daily basis,'' Dr. Pisano adds.
Genomic Solutions Inc. designs, develops, manufactures, markets and sells instruments, software, consumables and services used to determine the activity level of genes and to isolate, identify and characterize proteins. The company's products and systems enable researchers to perform complex, high volume experiments at a lower cost and in less time than traditional techniques. As a result, Genomic Solutions products and systems facilitate more rapid and less expensive drug discovery. Genomic Solutions markets products through its corporate headquarters in Ann Arbor, Michigan USA, and offices in the United Kingdom and Japan. Remaining worldwide distribution is provided by PerkinElmer Life Sciences through a strategic alliance with Genomic Solutions. The two companies also cooperate to sell co-branded products and collaborate to leverage their intellectual property and technologies. |
